NASDAQ:EDIT   Editas Medicine, Inc
Clearly a lot of value has been lost in the past month. The CSO stepped down and analysts downgraded projected revenue. EDIT has very lucrative candidates in the pipeline treating sickle cell anemia. Long-term, this company will most certainly be profitable, with significant patent protection. This is a short term down draft that is consolidating, for the near term, around a non-speculation, fair price of $63.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.